Mark Webb
Psychiatry · Ridgeland, MSNPI 1992843742
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,282 of the $11,882 with a category attached, or 69.7%. 27 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 37.6% of the total. Reporting peaked in 2019 at $4,863 and has fallen 73.6% since, to $1,282 in 2025. Among psychiatry clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 459 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$720
- Supernus Pharmaceuticals, Inc.$555
- Lundbeck LLC$420
- plus $3K from 21 others
What the payments were for
- Speaking & faculty fees$3,60030%
- Food & beverage$8,28270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $4,467 |
| AbbVie(2 entities) | 129 | $1,916 |
| Otsuka America Pharmaceutical, Inc. | 48 | $1,025 |
| Vanda Pharmaceuticals Inc. | 37 | $720 |
| Supernus Pharmaceuticals, Inc. | 29 | $555 |
| Lundbeck LLC | 20 | $420 |
| Axsome Therapeutics, Inc. | 18 | $400 |
| Tris Pharma Inc | 18 | $333 |
| Johnson & Johnson | 17 | $257 |
| Teva Pharmaceuticals USA, Inc. | 12 | $236 |
| Eisai Inc. | 11 | $198 |
| Merck | 13 | $198 |
| Ironshore Pharmaceuticals Inc. | 10 | $186 |
| E.r. Squibb & Sons, L.L.C. | 7 | $171 |
| Jazz Pharmaceuticals Inc. | 8 | $156 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $150 |
| Neurocrine Biosciences, Inc. | 7 | $129 |
| Collegium Pharmaceutical, Inc. | 6 | $120 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Corium, LLC | 2 | $38 |
| Shire North American Group Inc | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Biogen | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINTELLIX$3,600
- QELBREE$121
How this compares
$11,882 in reported general payments places this provider in the 95th percentile of 219 psychiatry providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $89,548 |
| Lurasidone Hcl | 30 | $4,500 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 43 | $1,884 |
| Duloxetine Hcl | 106 | $1,699 |
| Alprazolam | 183 | $1,105 |
| Fluvoxamine Maleate | 21 | $923 |
| Bupropion XlBupropion Hcl | 49 | $646 |
| Eszopiclone | 18 | $632 |
| Amitriptyline Hcl | 17 | $598 |
| Paroxetine Hcl | 41 | $412 |
| Lamotrigine | 43 | $378 |
| Buspirone Hcl | 84 | $375 |
| Sertraline Hcl | 59 | $349 |
| Clonazepam | 43 | $333 |
| Nortriptyline Hcl | 13 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $129 | $89,54811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 psychiatry providers in Mississippi.
Other psychiatry in Ridgeland
- Kurt BuechlerRidgeland$1.1M
- Clyde GlennRidgeland$68K
- Susan YoungerRidgeland$8K
- Mark McLainRidgeland$6K
- Fawaz AbdrabboRidgeland$4K
- Avani PatelRidgeland$4K
- Maxie GordonClinton$1.3M
- Chasity TorrenceWhitfield$834K
- Jon JacksonJackson$834K
- John NortonJackson$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.